research Synthesis, Characterization and Evaluation of 5α, 6β-Dihalo Androsterone Derivatives as 5α-Reductase Inhibitors
Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
Search
for
Sort by
Research
750-780 / 1000+ resultsresearch Referee report. For: Recent advances in treatment for Benign Prostatic Hyperplasia [version 1; referees: 2 approved]
BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.
research Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician
Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.
research Experimental Assessment of 3-meta-Pyridine-1,2,4-Oxadiazole Deoxycholic Acid Derivative as a Prototype of 5-α-Reductase Inhibitors in silico and in vivo Models
The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
research Risks and side effects in the medical management of benign prostatic hyperplasia
Medications for BPH can have significant side effects, so understanding these risks is important for treatment decisions.
research Recent advances in treatment for Benign Prostatic Hyperplasia
BPH treatments are improving with personalized medicine and better surgical options.
research Effect of a novel steroid (PM-9) on the inhibition of 5α-reductase present in Penicillium crustosum broths
PM-9 and finasteride effectively inhibit the enzyme that converts testosterone to DHT.
research Synthesis and Pharmacological Evaluation of New 16-Methyl Pregnane Derivatives.
New pregnane derivatives were more effective than finasteride at inhibiting a key enzyme for male pattern baldness.
research Plasma androsterone/epiandrosterone sulfates as markers of 5α-reductase activity: Effect of finasteride in normal men
Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.
research Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content*
A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
research Clinical risk factors associated with intraoperative floppy iris syndrome: a prospective study
Taking tamsulosin or finasteride and being older increase the risk of floppy iris during cataract surgery.
research Development of optimized self-nanoemulsifying lyophilized tablets (SNELTs) to improve finasteride clinical pharmacokinetic behavior
Improved tablets lead to faster, better drug absorption for hair loss treatment.
research Long-term use of 5α-reductase inhibitors and the risk of male breast cancer
Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.
research The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms – a review
Cyproterone acetate with ethinyl estradiol is effective for treating skin symptoms related to high androgen levels, like in PCOS.
research Hormone Treatment for the Adult Transgender Patient
Hormone therapy is safe and effective for transgender adults, but requires regular monitoring and mental health support.
research When two plus two must not equal four
Regulatory challenges make developing combination therapies in urology difficult and costly.
research Dual effects of 5α-reductase inhibitor dutasteride on androgenetic alopecia and acne vulgaris
Dutasteride improved both hair loss and acne in two young men.
research 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review
Prostate cancer is common, but risk can be reduced by avoiding smoking, unhealthy diet, inactivity, certain medications, and risky jobs.
research Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
research DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
research ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer
ERG increases SOX9, promoting prostate cancer growth and invasion.
research A Review on the Clinical Utility of PSA in Cancer Prostate
PSA is best for detecting prostate cancer recurrence and evaluating treatment response.
research Understanding the Epidemiology, Natural History, and Key Pathways Involved in Prostate Cancer
Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.
research Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99mTc-Radioimaging Agents
Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.
research The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention
5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
research Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer
Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.
research Activated Polyamine Catabolism Depletes Acetyl-CoA Pools and Suppresses Prostate Tumor Growth in TRAMP Mice
Overexpressing SSAT enzyme reduces prostate tumor growth in mice.
research Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial
Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.
research The Effect of 5α-Reductase Inhibition With Dutasteride and Finasteride on Bone Mineral Density, Serum Lipoproteins, Hemoglobin, Prostate Specific Antigen and Sexual Function in Healthy Young Men
Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
research Prostate cancer prevention
Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.